This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of glatiramer acetate
MSMED_GLATIRAMERACETATE
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
648 |
4. Check minimum number of events
Min. number of events
3
|
648 |
5. Include endpointsNone |
648 |
6. Filter based on genotype QC (FinnGen only) |
623 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of glatiramer acetate
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Other degenerative diseases of the nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 623 | 520 | 103 |
| Unadjusted period prevalence (%) | 0.16 | 0.18 | 0.05 |
| Median age at first event (years) | 38.30 | 37.84 | 40.64 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 648
- Matched controls
- 6480
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
1690.6
307.7
577
31
L04AX07
ATC
dimethyl fumarate; oral
144.9
307.7
163
15
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
29.8
307.7
390
313
L03AX13
ATC
glatiramer acetate; parenteral
+∞
307.7
648
5
H46
ICD-10 Finland
Optic neuritis
99.7
307.7
219
33
N86
ICPC
Multiple sclerosis
301.6
307.7
256
14
109
Kela drug reimbursment
Multiple sclerosis
5953.1
307.7
628
34
G35
ICD-10 Finland
Multiple sclerosis
+∞
307.7
648
52
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
114.7
307.7
188
23
L03AB07
ATC
interferon beta-1a; parenteral
344.3
307.7
326
19
N04BB01
ATC
amantadine; oral
96.9
307.7
187
27
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
6556.7
307.7
626
28
M03BX01
ATC
baclofen; systemic
38.6
237.4
152
51
164
Kela drug reimbursment
Fingolimod
308.9
201.2
195
9
L03AB08
ATC
interferon beta-1b; parenteral
586.0
183.9
174
*
TAB00
NOMESCO Finland
Lumbar puncture
14.9
182.8
185
169
353
Kela drug reimbursment
Cladribine and fingolimod
323.0
172.7
168
7
XKD06
NOMESCO Finland
Physiologic investigation of micturition
31.3
166.0
112
43
XCK00
NOMESCO Finland
Perimetry
17.3
165.9
149
110
L04AA27
ATC
[U] fingolimod
353.1
164.9
160
6
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
26.0
162.8
118
55
G04BD09
ATC
trospium; oral
39.2
159.8
100
30
N06BA07
ATC
modafinil; oral
87.6
158.6
84
11
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
36.8
156.8
100
32
XKD00
NOMESCO Finland
Uroflowmetry
13.6
153.3
161
154
XA800
NOMESCO Finland
Neuropsychological investigation
13.4
151.0
160
155
L04AA31
ATC
[U] teriflunomide
230.7
144.3
144
8
G04BD12
ATC
mirabegron; oral
10.9
136.1
169
204
ZX120
NOMESCO Finland
Intravenous
9.5
133.3
189
270
N07XX09
ATC
[U] dimethyl fumarate
163.2
116.6
120
9
Z01.0
ICD-10 Finland
Examination of eyes and vision
6.6
116.1
262
607
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
10.4
102.9
126
147
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
13.1
94.5
96
85
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
18.5
93.2
77
47
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
52.4
91.7
53
11
TKC22
NOMESCO Finland
Catheterisation instruction
31.4
90.6
60
21
XKC03
NOMESCO Finland
Water cystometry
15.2
89.4
82
61
G04BD04
ATC
oxybutynin; oral, transdermal
11.6
88.9
98
98
G04BD07
ATC
tolterodine; oral
13.2
88.7
89
77
N03AE01
ATC
clonazepam; systemic
8.9
87.3
120
161
H02AB04
ATC
methylprednisolone; systemic
5.5
85.0
212
522
R1250
NOMESCO Finland
Evaluation of functional capability
14.3
84.3
80
63
G04BD08
ATC
solifenacin; oral
10.4
83.2
99
110
2AB04, ,
NOMESCO Finland
158.3
80.1
83
6
UKC02
NOMESCO Finland
Cystoscopy
6.4
76.8
150
293
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
6.1
76.1
158
327
SPAT1229
SPAT
Assessment of need for aid
9.6
71.7
90
107
R20.2
ICD-10 Finland
Paraesthesia of skin
5.8
66.4
142
300
G04BD11
ATC
fesoterodine; oral
21.5
63.2
48
24
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.6
61.2
134
288
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
633.5
59.7
58
*
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
12.4
59.5
61
54
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.4
56.7
103
185
L04AE01
ATC
fingolimod; oral
597.5
56.5
55
*
N03AX12
ATC
[U] gabapentin; oral
4.1
55.8
197
618
H53.2
ICD-10 Finland
Diplopia
10.2
55.4
65
70
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
8.5
55.1
75
98
XCW99
NOMESCO Finland
Other investigative procedure of eye
5.6
54.5
116
242
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
147.0
51.7
54
*
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
8.1
51.5
73
100
R33
ICD-10 Finland
Retention of urine
9.2
51.0
65
78
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
21.2
49.8
38
19
Z2445
NOMESCO Finland
Psychologist
6.4
48.8
88
156
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
11.2
47.0
51
49
4AA23, ,
NOMESCO Finland
172.5
46.5
48
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
16.3
46.4
40
26
R35
ICD-10 Finland
Polyuria
6.2
42.6
78
140
Z3226
NOMESCO Finland
Physiotherapist
3.6
42.1
181
637
A06AD11
ATC
lactulose; oral
4.8
40.4
102
244
TKC20
NOMESCO Finland
Catheterisation of bladder
6.6
39.1
66
109
XKD03
NOMESCO Finland
Urethral pressure profilometry
11.5
37.6
40
37
A28
ICPC
Limited function/disability NOS
4.6
37.0
96
234
C10AC01
ATC
colestyramine; oral
7.5
35.7
53
76
L04AG12
ATC
ofatumumab; parenteral
366.1
35.3
35
*
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
190.2
35.1
36
*
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
54.5
34.9
41
8
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.9
34.2
82
187
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
4.5
34.0
91
227
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
43.7
33.5
41
10
N05CF01
ATC
zopiclone; oral
2.8
33.4
256
1232
R4150
NOMESCO Finland
Neuropsychological rehabilitation
12.4
32.7
33
28
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
7.9
32.6
46
62
N03AX16
ATC
[U] pregabalin
2.9
32.3
208
911
L03AB13
ATC
peginterferon beta-1a; parenteral
119.4
32.0
34
*
N02BF01
ATC
gabapentin; oral
4.1
31.7
98
272
J01EA01
ATC
trimethoprim; systemic
2.7
31.6
248
1203
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.4
30.3
127
433
Z3231
NOMESCO Finland
Registered nurse
2.7
29.7
225
1066
L04AX01
ATC
azathioprine; systemic
5.2
29.7
64
133
R5110, ,
SPAT
5.4
29.5
61
122
XCD10
NOMESCO Finland
Electrophysiological examination of eye
8.4
29.3
39
49
L04AK02
ATC
teriflunomide; oral
84.1
29.0
32
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
157.0
28.9
30
*
L04AA52
ATC
[U] ofatumumab; parenteral
+∞
28.3
27
*
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
8.8
28.1
36
43
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.7
27.8
68
157
L28
ICPC
Limited function/disability (L)
3.4
27.5
115
390
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
56.0
27.4
32
6
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.7
27.3
201
933
G04CA02
ATC
tamsulosin; oral
4.2
26.8
77
202
R4120
NOMESCO Finland
Occupational therapy
4.1
26.2
78
210
N29
ICPC
Neurological sympt/complt other
8.6
25.5
33
40
L04AA40
ATC
cladribine; oral
135.2
24.8
26
*
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
3.0
24.6
129
498
SPAT1215
SPAT
Assessment of need for medical rehabilitation
5.1
24.3
53
111
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
124.4
22.7
24
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.8
22.4
72
204
N28
ICPC
Limited function/disability (N)
20.4
22.3
33
17
R4110
NOMESCO Finland
Physiotherapy
2.4
21.8
200
1014
N39.4
ICD-10 Finland
Other specified urinary incontinence
3.7
21.8
73
213
N03AF01
ATC
carbamazepine; oral, rectal
4.3
21.6
58
144
G04CA01
ATC
alfuzosin; oral
4.6
21.5
53
123
U13
ICPC
Bladder symptom/complaint other
6.3
21.0
36
60
N06AX16
ATC
venlafaxine; oral
2.5
20.5
161
759
A02BC02
ATC
pantoprazole; systemic
2.3
19.8
455
3306
N31.1
ICD-10 Finland
Reflex neuropathic bladder, not elsewhere classified
27.0
19.3
26
10
G36.0
ICD-10 Finland
Neuromyelitis optica [Devic]
72.1
18.8
21
*
H02AB07
ATC
prednisone; oral
2.8
18.7
109
442
KA1AE
NOMESCO Finland
Kidney ultrasound examination
7.4
18.4
27
38
H49.2
ICD-10 Finland
Sixth [abducent] nerve palsy
22.5
18.3
26
12
U07
ICPC
Urine symptom/complaint other
3.7
18.0
61
179
N30.0
ICD-10 Finland
Acute cystitis
2.4
17.9
144
682
RF120, ,
NOMESCO Finland
16.2
17.6
28
18
N30.9
ICD-10 Finland
Cystitis, unspecified
3.6
17.0
58
171
TPH04
NOMESCO Finland
Cathetrisation of vein
2.4
17.0
147
718
Z50.1
ICD-10 Finland
Other physical therapy
4.3
16.9
45
111
H53.1
ICD-10 Finland
Subjective visual disturbances
3.3
16.8
69
229
SPAT1231
SPAT
Assessment of adjustments needed in living environment
16.9
16.7
26
16
R39.1
ICD-10 Finland
Other difficulties with micturition
6.3
16.5
28
46
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
4.0
16.1
47
124
G50.0
ICD-10 Finland
Trigeminal neuralgia
5.6
16.0
31
58
U04
ICPC
Incontinence urine
4.7
15.8
37
82
N31.2
ICD-10 Finland
Flaccid neuropathic bladder, not elsewhere classified
16.2
15.8
25
16
N06AB04
ATC
citalopram; systemic
2.2
15.7
171
915
H51.2
ICD-10 Finland
Internuclear ophthalmoplegia
+∞
15.7
15
*
N04BC05
ATC
pramipexole; oral
3.4
15.6
59
186
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
15.2
15.5
25
17
N06AX21
ATC
duloxetine; oral
2.4
15.3
120
559
SPAT1216
SPAT
Assessment of functional ability
2.8
15.1
82
319
J01CA08
ATC
pivmecillinam; oral
1.9
15.0
351
2456
L04AX09
ATC
diroximel fumarate; oral
+∞
14.6
14
*
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
4.0
14.5
42
110
RS221, ,
NOMESCO Finland
6.6
14.2
23
36
SPAT1262
SPAT
Handing over of treatment supplies
2.5
14.0
100
446
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
4.8
13.9
32
70
R42
ICD-10 Finland
Dizziness and giddiness
2.2
13.3
132
677
Z2446
NOMESCO Finland
Social worker
3.0
12.9
61
220
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
14.4
12.8
21
15
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
2.5
12.8
89
391
34099
ICD-8 Finland
Multiple sclerosis
+∞
12.5
12
*
N31.0
ICD-10 Finland
Uninhibited neuropathic bladder, not elsewhere classified
24.9
12.5
17
7
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
2.5
12.5
82
350
N32.82
ICD-10 Finland
Instability of the detrusor vesicae muscle
13.5
12.5
21
16
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.6
12.4
75
308
N06AA09
ATC
amitriptyline; systemic
2.7
12.3
70
278
G04BD10
ATC
darifenacin; oral
47.6
11.9
14
*
SPAT1137
SPAT
Taking care of patient’s/customer’s hygiene
6.0
11.9
21
36
N03AF02
ATC
oxcarbazepine; oral
3.6
11.7
39
113
N02BF02
ATC
pregabalin; oral
2.9
11.7
56
203
RF420, ,
NOMESCO Finland
8.9
11.6
24
28
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
11.6
170
1002
M03BX02
ATC
tizanidine; oral
1.9
11.6
465
3725
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
3.5
11.6
40
119
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
4.5
11.5
28
64
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
11.5
11
*
4AA36, ,
NOMESCO Finland
122.1
11.5
12
*
R15
ICD-10 Finland
Faecal incontinence
5.5
11.4
22
41
H47.2
ICD-10 Finland
Optic atrophy
35.7
11.3
14
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.8
11.2
233
1531
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
20.5
11.2
16
8
U05
ICPC
Urination problems other
4.1
11.1
31
79
R32
ICD-10 Finland
Unspecified urinary incontinence
5.4
11.1
22
42
U08
ICPC
Urinary retention
14.2
11.0
18
13
359
Kela drug reimbursment
Mirabegroni
28.6
10.8
14
5
U02
ICPC
Urinary frequency/urgency
2.2
10.7
97
477
N04BD01
ATC
selegiline; oral
13.2
10.7
18
14
N99
ICPC
Neurological disease other
11.5
10.6
19
17
RF410, ,
NOMESCO Finland
9.4
10.6
21
23
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
10.3
10.6
20
20
RS340, ,
NOMESCO Finland
+∞
10.4
10
*
3773B
ICD-9 Finland
Disorders of optic nerve and visual pathways, Optic neuritis[NEURITIS RETROBULBARIS]
+∞
10.4
10
*
XF400
NOMESCO Finland
ECG with 12 standard connections
2.3
10.1
80
371
A06AC01
ATC
ispaghula (psylla seeds); oral
1.9
10.1
154
914
DM1QA
NOMESCO Finland
Paranasal sinuses X-ray examination in one projection
3.1
9.9
42
142
XCK10
NOMESCO Finland
Photography of fundus of eye
2.7
9.9
55
216
K59.0
ICD-10 Finland
Constipation
3.4
9.9
35
106
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
5.0
9.8
21
43
CS494
NOMESCO Finland
Other visual field testing
5.4
9.7
19
36
Z43.5
ICD-10 Finland
Attention to cystostomy
55.8
9.7
11
*
SPAT1325
SPAT
Vaccination
1.8
9.7
170
1055
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
3.6
9.6
32
93
C03CA01
ATC
furosemide; systemic
2.2
9.5
83
402
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.9
9.5
152
916
H47.0
ICD-10 Finland
Disorders of optic nerve, not elsewhere classified
101.5
9.4
10
*
ABD40
NOMESCO Finland
Implantation of spinal injection device
+∞
9.4
9
*
J01MA02
ATC
ciprofloxacin; systemic
1.7
9.3
218
1468
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
9.2
55
224
G04BE03
ATC
sildenafil; oral
15.9
9.1
14
9
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
10.2
8.6
16
16
K59.00
ICD-10 Finland
Constipation caused by slow bowel passage (SCT)
6.8
8.4
20
30
A02BA02
ATC
ranitidine; systemic
2.0
8.4
103
566
RF432, ,
NOMESCO Finland
+∞
8.3
8
*
H48.1
ICD-10 Finland
Retrobulbar neuritis in diseases classified elsewhere
+∞
8.3
8
*
H52.1
ICD-10 Finland
Myopia
2.8
8.3
41
151
L89
ICD-10 Finland
Decubitus ulcer and pressure area
10.9
8.3
15
14
Z3229
NOMESCO Finland
Other healthcare associate professional
2.5
8.3
51
211
J05AB01
ATC
aciclovir; systemic
1.7
8.2
167
1076
SDA04
NOMESCO Finland
Demanding periodontal treatment
1.7
8.1
205
1400
SPAT1167
SPAT
Insertion of urinary catheter
8.3
8.1
17
21
6BA02, ,
NOMESCO Finland
17.4
8.1
12
7
R03CA02
ATC
ephedrine; oral
33.8
8.1
10
*
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.2
8.1
68
324
R60.0
ICD-10 Finland
Localized oedema
2.3
8.0
62
285
F32.9
ICD-10 Finland
Depressive episode, unspecified
1.9
8.0
114
660
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.2
7.9
67
320
N18
ICPC
Paralysis/weakness
9.6
7.8
15
16
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
15.2
7.7
12
8
G04BDXX, ,
ATC
45.5
7.7
9
*
K59.09
ICD-10 Finland
Constipation, unspecified
2.9
7.7
36
129
H57.1
ICD-10 Finland
Ocular pain
2.7
7.7
40
152
CA1CG
NOMESCO Finland
Eye and orbita extensive MRI examination with high intensity magnet
10.2
7.6
14
14
J05AB11
ATC
valaciclovir; oral
1.9
7.5
105
602
L01BB04
ATC
cladribine; systemic
81.0
7.4
8
*
SPAT1256
SPAT
Intramuscular and subcutaneous injection
1.6
7.4
218
1542
H02AB06
ATC
prednisolone; systemic
1.6
7.3
289
2190
119
Kela drug reimbursment
Trigeminal neuralgia or glossofaryngeusneuralgia
15.9
7.2
11
7
R31
ICD-10 Finland
Unspecified haematuria
2.7
7.0
37
142
AA1AD
NOMESCO Finland
CT of head and brain
1.8
6.9
120
735
R51.80
ICD-10 Finland
Headache
1.7
6.9
129
807
U28
ICPC
Limited function/disability (U)
14.0
6.9
11
8
OAB50, ,
SPAT
2.8
6.9
33
120
U29
ICPC
Urinary symptom/complaint other
3.9
6.9
20
53
R1230
NOMESCO Finland
Neuropsychological evaluation of need and possibilities to rehabilitation
9.4
6.8
13
14
WW400
NOMESCO Finland
Plasmaferesis
40.5
6.8
8
*
G82.2
ICD-10 Finland
Paraplegia, unspecified
22.8
6.7
9
*
Z01.2
ICD-10 Finland
Dental examination
1.5
6.7
315
2469
OAB43, ,
SPAT
0.6
6.7
175
2421
G51.0
ICD-10 Finland
Bell palsy
3.6
6.6
21
59
SPAT1263
SPAT
Sampling
1.6
6.6
250
1864
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
6.6
139
899
H53.4
ICD-10 Finland
Visual field defects
4.2
6.6
17
41
A04
ICPC
Weakness/tiredness general
1.9
6.6
89
505
RS230, ,
NOMESCO Finland
10.2
6.6
12
12
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.2
6.5
55
262
RF310, ,
NOMESCO Finland
70.5
6.4
7
*
1DB07, ,
NOMESCO Finland
70.5
6.4
7
*
Y57
ICD-10 Finland
Adverse effects in the therapeutic use of other and unspecified drugs and medicaments
3.7
6.4
20
56
J01MA06
ATC
norfloxacin; oral
1.9
6.3
86
488
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
5.6
6.3
17
31
R4120, ,
SPAT
11.2
6.3
11
10
M05BA04
ATC
alendronic acid; oral
3.1
6.3
26
87
R06AE07
ATC
cetirizine; oral
1.5
6.3
314
2481
Z93.5
ICD-10 Finland
Cystostomy status
+∞
6.3
6
*
N07AA03
ATC
distigmine; systemic
27.0
6.2
8
*
SPAT1234
SPAT
Support of social functional capacity
3.0
6.2
27
93
R74.0
ICD-10 Finland
Elevation of levels of transaminase and lactic acid dehydrogenase [LDH]
3.5
6.2
21
62
R13
ICD-10 Finland
Dysphagia
2.5
6.1
39
165
J01XX05
ATC
methenamine; oral
8.7
6.1
12
14
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
111
10
133.74
220.29
3.2
2.3
—
—
—
0
0
157
95
21.49
194.47
1.2
1.1
—
—
—
0
0
217
396
7.74
122.69
3.7
2.5
9.51
10.30
g/l
3.18
199
366
83
35
27.05
118.10
4.5
2.6
470.96
456.59
e6/l
0.10
72
29
143
182
9.80
109.52
1.8
1.6
0.01
0.01
iu/ml
—
8
22
169
307
7.09
94.17
3.7
1.7
0.99
1.21
g/l
2.91
163
287
549
2768
7.44
91.76
15.7
5.5
1.57
1.97
e9/l
11.80
532
2528
519
2520
6.32
89.84
15.1
5.5
3.23
2.72
%
5.27
514
2387
526
2630
6.31
86.44
15.0
5.5
25.70
29.45
%
14.32
521
2509
521
2606
6.10
84.93
14.7
5.3
59.53
56.76
%
7.29
516
2480
64
32
22.08
84.62
2.6
2.3
—
—
—
0
0
550
3059
6.28
73.65
16.0
8.4
3.59
3.95
e9/l
5.68
535
2717
259
882
4.23
67.01
4.8
2.2
4.51
8.37
e6/l
3.20
238
788
318
1287
3.89
63.54
6.4
2.5
13.05
52.94
e6/l
2.44
275
959
49
27
19.55
61.77
1.2
1.1
1760.33
1775.74
miu/ml
0.02
49
27
297
1170
3.84
61.34
5.7
2.4
0.14
0.37
e6/l
2.35
253
860
41
15
29.11
60.61
6.3
3.1
—
—
—
0
0
56
43
14.16
59.51
1.0
1.1
—
—
—
0
0
68
76
9.88
56.43
1.2
1.1
—
—
—
0
0
546
3362
4.96
55.15
10.2
3.5
72.45
467.00
e6/l
0.52
11
35
57
52
11.92
54.43
1.1
1.1
50.94
29.33
mg/l
3.29
40
39
55
49
12.17
53.31
1.0
1.1
209.47
228.25
mg/l
0.37
40
40
415
2178
3.52
52.19
2.7
2.3
97.60
74.38
nmol/l
29.23
395
2041
191
667
3.64
45.32
4.7
2.2
0.94
1.01
e6/l
0.14
118
349
174
615
3.50
40.01
5.0
2.2
5.73
3.95
e6/l
0.62
102
298
70
132
5.82
36.21
1.1
1.5
421.94
421.25
mg/l
0.01
64
122
46
59
8.32
34.02
1.0
1.1
—
—
—
0
0
428
2655
2.80
33.74
6.7
3.0
0.00
0.01
estimate
0.80
102
495
424
2622
2.79
33.56
8.9
4.1
0.00
0.00
estimate
0.50
101
518
46
61
8.04
33.09
1.0
1.1
—
—
—
0
0
422
2628
2.74
32.50
6.8
2.9
0.00
0.00
estimate
0.50
105
539
45
63
7.60
30.88
1.0
1.1
—
—
—
0
0
61
119
5.55
30.34
1.2
1.8
587.81
171.13
e6/l
0.48
48
98
61
119
5.55
30.34
1.1
1.7
8.47
5.01
e6/l
1.15
47
94
34
8
44.69
27.99
1.1
1.0
—
—
—
0
0
35
42
8.75
27.23
1.0
1.1
0.93
1.07
u/l
0.96
11
23
382
2437
2.38
25.30
5.5
5.4
9.39
9.63
umol/l
0.37
364
2307
51
114
4.77
21.63
4.0
4.1
3.65
4.40
e9/l
1.77
51
114
117
459
2.89
21.50
2.5
2.0
5605.77
4035.65
u/l
0.15
36
193
51
116
4.69
21.18
4.1
4.5
61.41
57.74
%
1.35
51
116
133
570
2.68
20.59
2.3
2.0
29.35
29.46
s
0.09
126
556
49
120
4.34
18.54
1.1
1.4
3.62
3.60
mmol/l
0.06
43
112
63
210
3.22
15.22
1.5
1.4
—
—
—
0
0
309
2072
1.94
15.05
7.5
2.9
—
—
—
0
0
17
5
34.85
13.56
1.1
1.2
—
—
—
0
0
206
1240
1.97
13.48
2.8
1.4
1.92
2.19
g/l
2.61
159
819
82
349
2.55
12.59
2.5
1.7
—
—
—
0
0
270
1815
1.84
12.35
4.4
4.5
37.33
37.13
g/l
0.25
251
1713
214
1339
1.89
12.28
8.5
3.2
0.00
0.01
estimate
1.08
100
514
19
13
15.01
11.85
2.3
2.2
—
—
—
0
0
476
5436
0.53
10.61
3.4
3.6
1.50
1.51
mmol/l
0.26
437
5211
178
1094
1.86
10.55
7.5
3.1
1.02
1.02
kg/l
0.42
27
147
470
3835
1.82
10.33
6.9
6.6
73.62
73.80
u/l
0.04
440
3646
452
5230
0.55
10.27
3.1
3.3
1.32
1.26
mmol/l
1.03
421
4996
354
2684
1.70
9.93
4.6
4.1
6.08
6.39
mmol/l
2.81
334
2455
486
5493
0.54
9.79
3.7
3.8
3.01
2.94
mmol/l
0.95
446
5254
482
5453
0.55
9.52
3.4
3.6
4.93
4.87
mmol/l
0.84
448
5249
44
159
2.90
9.26
1.4
1.6
—
—
—
0
0
633
5851
4.54
9.21
17.9
8.5
27.60
25.96
u/l
1.80
624
5726
595
5355
2.36
8.56
13.3
9.9
139.81
139.62
mmol/l
1.46
587
5230
596
5377
2.35
8.36
13.4
10.0
3.90
3.91
mmol/l
0.72
586
5239
236
1673
1.65
8.09
6.0
6.9
1.00
1.07
inr
4.45
70
562
20
49
4.18
7.58
1.2
1.6
—
—
—
0
0
259
1902
1.60
7.57
5.2
3.1
28.54
28.90
u/l
0.08
249
1816
604
5520
2.39
7.52
14.1
10.0
18.62
18.63
mg/l
0.00
478
4192
481
4106
1.67
7.33
4.9
2.9
49.33
38.91
u/l
1.49
464
3957
102
591
1.86
7.07
1.6
1.7
—
—
—
0
0
71
387
1.94
5.91
1.6
1.6
—
—
—
0
0
38
786
0.45
5.57
1.5
1.6
—
—
—
0
0
71
400
1.87
5.36
1.6
1.6
—
—
—
0
0
261
2049
1.46
5.06
6.7
5.9
1.22
1.22
mmol/l
0.22
221
1749
71
421
1.77
4.55
7.7
6.6
104.75
104.72
mmol/l
0.01
71
421
168
1249
1.47
4.19
1.9
2.0
194.94
208.69
u/l
0.07
161
1189
228
1801
1.41
4.07
6.7
5.2
1.22
1.22
mmol/l
0.30
208
1668
84
543
1.63
3.94
2.4
2.5
6.74
5.04
umol/l
0.74
77
459
123
873
1.50
3.83
1.5
1.4
22.36
21.21
nmol/l
0.34
107
781
427
4729
0.72
3.83
4.0
4.2
36.94
38.02
mmol/mol
1.80
396
4522
102
704
1.53
3.62
2.6
2.8
333.49
353.83
ng/l
0.04
45
374
207
1649
1.38
3.41
1.8
1.8
98.79
98.01
pmol/l
0.08
103
916
13
38
3.47
3.32
1.1
1.1
—
—
—
0
0
551
5135
1.49
3.24
12.8
8.3
96.73
92.04
ml/min/173m2
8.20
476
4211
34
185
1.88
2.93
2.7
2.0
11.54
5.48
iu/l
1.04
15
73
79
1094
0.68
2.59
1.2
1.3
1.65
11.48
u/ml
4.53
28
479
28
150
1.91
2.55
11.6
2.5
0.63
0.70
%
0.59
28
150
12
45
2.70
2.46
1.5
1.2
—
—
—
0
0
15
64
2.38
2.40
1.7
2.5
0.70
1.23
%
0.76
15
58
639
6262
2.47
2.35
28.4
15.1
40.44
40.40
%
0.08
605
5996
46
295
1.60
2.29
8.6
3.3
5.83
5.81
kpa
0.05
46
288
47
311
1.55
2.07
1.1
1.3
264.71
239.07
miu/ml
0.14
17
165
6
15
4.03
2.04
1.0
1.1
79.67
98.87
%
—
6
15
86
1127
0.73
2.04
1.3
1.3
9.46
24.51
iu/ml
6.66
19
394
17
83
2.08
2.02
1.2
1.2
—
—
—
0
0
22
382
0.56
1.95
1.3
1.5
—
—
—
0
0
18
329
0.53
1.90
1.3
1.7
5.11
3.12
mg/l
—
9
229
485
5126
0.79
1.88
3.4
3.5
5.60
5.67
mmol/l
0.64
444
4852
21
117
1.82
1.76
1.6
1.8
—
—
—
0
0
23
380
0.59
1.72
1.4
1.5
—
—
—
0
0
176
1490
1.25
1.72
2.3
2.5
51.44
56.17
u/l
1.45
162
1405
64
853
0.72
1.69
1.8
1.8
1.52
1.35
%
1.50
58
784
37
244
1.55
1.69
9.8
2.5
4.73
4.88
kpa
0.17
37
239
422
3915
1.22
1.67
2.9
3.7
9.49
9.22
mm/h
0.21
390
3706
7
25
2.82
1.65
1.1
1.2
—
—
—
0
0
170
1441
1.24
1.63
1.3
1.3
0.88
1.79
u/ml
0.96
39
413
40
272
1.50
1.60
2.1
1.7
—
—
—
0
0
79
609
1.34
1.58
2.3
2.1
2.57
2.45
g/l
1.16
74
564
26
160
1.65
1.58
1.8
1.9
—
—
—
0
0
5
15
3.35
1.52
2.8
1.9
47.52
54.05
ug/l
—
5
15
24
147
1.66
1.49
1.9
1.7
—
—
—
0
0
78
607
1.32
1.48
1.6
1.6
1096.92
1176.82
nmol/l
0.38
62
491
448
4736
0.82
1.45
3.6
3.7
—
—
—
0
0
5
16
3.14
1.44
1.2
1.1
—
—
—
0
0
85
673
1.30
1.43
2.5
2.2
15.59
14.80
umol/l
0.35
78
625
544
5218
1.27
1.40
6.2
4.8
1.61
1.94
mu/l
0.85
520
4990
108
885
1.26
1.39
1.4
1.6
477.62
25686215.40
pmol/l
1.05
98
802
9
41
2.21
1.37
1.0
1.2
—
—
—
0
0
16
90
1.80
1.34
1.3
4.0
—
329.00
—
0
10
58
440
1.35
1.32
2.6
2.3
24.81
33.29
u/l
2.10
43
370
13
69
1.90
1.29
1.3
2.7
—
983.00
—
0
6
12
62
1.95
1.28
1.4
1.8
—
—
—
0
0
26
171
1.54
1.25
1.5
1.4
28.68
23.09
u/l
0.36
18
141
41
297
1.41
1.24
11.2
6.8
1.23
1.26
mmol/l
0.06
41
290
5
19
2.64
1.22
2.4
3.0
7.90
17.36
umol/l
—
5
19
98
1174
0.81
1.19
1.8
2.2
4153.86
4601.41
umol/l
0.04
92
1077
10
50
2.02
1.17
1.2
1.1
259.60
290.60
mg/l
—
10
45
47
353
1.36
1.16
6.6
9.5
0.67
1.05
mmol/l
0.21
33
277
20
126
1.61
1.15
1.0
1.2
—
—
—
0
0
0
36
0.00
1.14
0.0
1.7
—
—
—
0
0
15
88
1.72
1.12
4.7
3.6
28.88
24.42
mg/l
—
9
58
68
543
1.28
1.11
2.5
2.2
26.21
24.74
%
0.28
54
461
7
31
2.27
1.10
1.4
1.1
—
—
—
0
0
52
401
1.32
1.09
2.4
2.6
—
—
—
0
0
88
727
1.24
1.08
2.2
2.8
571.69
543.53
ng/l
0.04
73
591
28
195
1.46
1.06
1.7
2.4
67.76
74.91
ng/l
0.15
21
172
25
358
0.69
1.05
1.3
1.4
—
—
—
0
0
25
357
0.69
1.04
1.3
1.4
—
—
—
0
0
17
263
0.64
1.04
1.4
1.6
—
—
—
0
0
12
201
0.59
1.01
1.2
1.4
82.32
115.80
pmol/l
0.25
12
195
25
355
0.69
1.01
1.3
1.4
—
—
—
0
0
25
355
0.69
1.01
1.3
1.4
—
—
—
0
0
13
76
1.73
0.99
1.1
1.2
—
—
—
0
0
13
76
1.73
0.99
1.1
1.2
—
—
—
0
0
7
36
1.95
0.97
2.4
1.7
2.57
0.90
u/field
—
7
28
0
32
0.00
0.95
0.0
9.6
—
44.77
—
0
13
15
93
1.63
0.94
1.6
2.3
377.33
280.05
ug/l
0.21
15
81
15
93
1.63
0.94
2.1
3.7
27.93
34.64
umol/l
1.38
15
85
7
37
1.90
0.94
1.6
2.4
106.00
106.00
mmol/l
—
7
37
10
169
0.59
0.89
1.3
1.2
—
—
—
0
0
10
168
0.59
0.87
1.3
1.2
—
—
—
0
0
17
112
1.53
0.85
1.0
1.3
1.33
4.25
u/ml
—
6
36
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
31
1.94
0.84
1.0
1.2
—
—
—
0
0
131
1155
1.17
0.84
2.0
1.9
—
—
—
0
0
111
1264
0.85
0.80
1.9
2.1
—
—
—
0
0
0
26
0.00
0.78
0.0
1.0
—
40.63
—
0
26
0
27
0.00
0.77
0.0
1.1
—
160.46
—
0
27
22
301
0.72
0.76
1.5
1.8
—
—
—
0
0
171
1551
1.14
0.75
1.6
1.5
—
—
—
0
0
17
116
1.48
0.75
1.0
1.3
3.00
6.07
u/ml
—
5
45
17
117
1.47
0.72
1.1
1.2
263.25
220.77
u/ml
0.23
12
73
94
1072
0.86
0.70
5.3
3.7
3.63
10.67
mg/mmol
2.54
63
685
10
61
1.65
0.69
1.0
1.5
—
—
—
0
0
26
196
1.34
0.68
1.2
1.3
—
—
—
0
0
9
59
1.53
0.68
1.2
1.3
—
—
—
0
0
11
166
0.66
0.65
1.1
1.0
0.48
1.86
u/ml
—
5
74
53
631
0.83
0.65
1.3
1.5
—
—
—
0
0
19
138
1.39
0.63
2.9
3.0
24.92
24.60
mmol/l
0.24
19
132
8
49
1.64
0.62
1.0
1.0
—
—
—
0
0
16
113
1.43
0.61
1.0
1.1
—
—
—
0
0
5
30
1.67
0.61
1.6
2.8
—
—
—
0
0
0
22
0.00
0.59
0.0
1.5
—
8.30
—
0
22
0
23
0.00
0.58
0.0
2.8
—
167.52
—
0
5
30
374
0.79
0.57
1.6
2.0
86.46
79.24
ml/min/173m2
0.69
13
145
8
54
1.49
0.57
1.1
1.4
62.63
72.50
umol/l
—
8
54
71
619
1.17
0.55
1.2
1.3
35.00
27.17
iu/l
0.93
63
527
78
688
1.15
0.53
2.0
2.3
2.43
2.41
mmol/l
0.88
61
606
165
1528
1.11
0.52
2.7
2.6
82.94
27.67
ng/l
0.50
80
711
50
583
0.85
0.51
1.5
1.8
—
—
—
0
0
14
191
0.73
0.51
1.1
1.1
0.51
2.48
u/ml
—
6
90
57
492
1.17
0.51
5.6
5.0
—
—
—
0
0
11
75
1.47
0.51
1.6
2.4
—
—
—
0
0
6
41
1.47
0.50
1.0
1.3
—
—
—
0
0
10
67
1.50
0.50
1.0
1.1
—
—
—
0
0
58
505
1.16
0.48
3.4
3.4
29.73
31.63
%
0.99
51
391
13
94
1.39
0.46
1.6
1.9
4.63
5.14
mmol/24h
0.25
13
81
125
1150
1.11
0.45
2.2
2.0
2.94
2.73
mg/l
0.38
107
1000
13
175
0.74
0.45
2.5
1.6
—
—
—
0
0
72
642
1.14
0.44
3.0
3.1
0.82
0.82
mmol/l
0.09
67
618
5
31
1.62
0.43
3.4
3.0
37980.00
37222.58
ug/l
—
5
31
466
4546
1.09
0.43
5.3
4.2
14.39
14.25
pmol/l
0.67
437
4311
15
113
1.34
0.43
1.8
1.6
—
—
—
0
0
8
56
1.43
0.42
1.4
1.4
—
—
—
0
0
35
412
0.84
0.42
1.6
1.5
—
—
—
0
0
5
33
1.52
0.41
1.2
1.5
7.18
6.91
u/l
—
5
28
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
0
17
0.00
0.40
0.0
1.0
—
593.83
—
0
12
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
0
17
0.00
0.40
0.0
1.0
—
33.91
—
0
11
159
1489
1.09
0.40
2.1
3.1
2.33
2.35
mmol/l
0.72
136
1374
8
60
1.34
0.40
1.5
1.1
—
—
—
0
0
115
1244
0.91
0.40
4.6
3.0
8.21
7.90
mmol/l
0.32
101
1119
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
69
765
0.89
0.38
1.6
1.9
—
—
—
0
0
14
108
1.30
0.35
1.2
1.4
—
—
—
0
0
257
2467
1.07
0.34
2.4
2.4
—
—
—
0
0
16
127
1.27
0.33
1.4
1.0
0.92
2.40
u/ml
—
6
68
11
144
0.76
0.33
1.2
1.1
—
—
—
0
0
6
46
1.31
0.33
1.2
1.4
—
—
—
0
0
43
379
1.14
0.33
1.1
1.1
—
—
—
0
0
6
47
1.28
0.32
2.2
3.2
41.83
64.05
u/ml
—
6
47
16
128
1.26
0.32
1.3
1.3
—
—
—
0
0
26
222
1.18
0.30
2.7
2.8
5.31
5.09
kpa
0.69
26
213
8
108
0.74
0.29
1.1
1.3
—
—
—
0
0
10
76
1.32
0.28
1.7
1.1
—
—
—
0
0
107
1136
0.93
0.26
1.8
2.0
—
—
—
0
0
5
75
0.66
0.26
1.0
1.5
—
—
—
0
0
5
75
0.66
0.26
1.0
1.5
—
—
—
0
0
9
73
1.24
0.25
1.1
1.4
—
—
—
0
0
132
1256
1.06
0.24
1.8
1.7
0.86
0.74
mg/l
0.30
84
935
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
8
101
0.79
0.21
1.1
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
5.1
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
18
208
0.86
0.20
1.5
1.9
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
0
14
0.00
0.20
0.0
2.0
—
—
—
0
0
6
52
1.16
0.19
1.2
1.4
—
—
—
0
0
280
2858
0.96
0.16
3.0
2.8
83.58
77.28
ug/l
0.18
265
2726
158
1531
1.04
0.15
1.6
1.6
—
—
—
0
0
37
342
1.09
0.15
1.4
1.6
—
—
—
0
0
19
213
0.89
0.15
1.2
1.5
—
—
—
0
0
9
82
1.10
0.15
1.0
1.2
—
—
—
0
0
28
305
0.91
0.14
2.0
4.2
2.47
7.27
ug/l
2.11
19
230
8
100
0.80
0.13
1.0
1.3
—
—
—
0
0
20
220
0.91
0.12
1.5
1.8
—
—
—
0
0
25
230
1.09
0.11
1.2
1.5
—
—
—
0
0
20
182
1.10
0.11
1.1
1.1
—
—
—
0
0
128
1314
0.97
0.10
1.6
1.7
1.54
1.42
mmol/l
0.66
106
1159
6
54
1.11
0.09
1.2
1.9
—
—
—
0
0
6
56
1.07
0.08
1.2
1.2
—
—
—
0
0
6
56
1.07
0.08
1.2
1.2
—
—
—
0
0
6
57
1.05
0.08
1.2
1.2
—
—
—
0
0
6
57
1.05
0.08
1.2
1.2
—
—
—
0
0
6
57
1.05
0.08
1.2
1.2
—
—
—
0
0
35
369
0.95
0.08
1.5
1.5
—
—
—
0
0
5
64
0.78
0.08
2.6
1.8
19.52
6.74
u/ml
—
5
64
7
64
1.09
0.08
1.1
1.4
—
—
—
0
0
7
85
0.82
0.07
3.0
2.4
—
—
—
0
0
18
167
1.08
0.07
1.1
1.2
—
2.62
—
0
21
30
315
0.95
0.06
1.7
2.3
0.61
0.65
ug/l
0.16
16
150
30
314
0.95
0.05
7.2
3.0
1.24
1.23
mmol/l
0.24
25
272
14
151
0.93
0.05
1.6
2.5
8.84
10.02
mg/l
0.27
14
140
44
427
1.03
0.04
2.5
3.3
22.37
21.27
%
0.12
17
141
29
299
0.97
0.02
1.4
1.5
—
—
—
0
0
57
563
1.01
0.01
1.3
1.2
224.15
161.85
iu/ml
0.42
21
243
12
114
1.05
0.00
1.9
1.8
—
—
—
0
0
11
115
0.96
0.00
1.0
1.1
—
—
—
0
0
14
144
0.97
0.00
1.6
1.3
281.14
323.92
ug/g
—
8
80
0
9
0.00
0.00
0.0
1.0
—
—
—
0
0
6
64
0.94
0.00
1.2
1.3
23.10
31.21
nmol/l
—
6
51
6
64
0.94
0.00
1.5
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.8
—
—
—
0
0
9
99
0.91
0.00
1.1
1.4
—
—
—
0
0
6
64
0.94
0.00
1.5
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
71
0.99
-0.00
1.3
1.3
—
—
—
0
0
6
62
0.97
-0.00
1.5
1.3
—
—
—
0
0
6
61
0.98
-0.00
1.5
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
62
0.97
-0.00
1.5
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.6
—
22.20
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
67.00
—
0
6
0
6
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
63
0.95
-0.00
1.5
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.7
—
36.03
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_GLATIRAMERACETATE – Use of glatiramer acetate
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).